Bio Special
Beyond Scale: What Will Sustain APAC’s Biopharma Leadership Asia-Pacific’s rise in global biopharma is no longer about whether the region can ...
January 21, 2026 | News | By Joonho Choi, Vice President, Asia-Pacific, Cytiva
As more APAC biotech and pharma companies look to Europe for regulatory approval and commercialisation, navigating complex EU and UK requirements early is ...
January 19, 2026 | News
Ventyx's clinical pipeline includes multiple small molecules with potential for oral therapies addressing chronic inflammation Acquisition builds on ...
January 09, 2026 | News
Real Change Starts with Listening Across the Asia Pacific, Middle East, and Africa, healthcare systems are facing mounting pressures with rising rates of ...
January 05, 2026 | Opinion | By Sung Lee, Executive Director, Region Communications and Patient Advocacy, Asia Pacific, Middle East, Africa (APMA), Novartis
As surgical volumes rise and care pathways grow more complex across Asia Pacific, the limitations of how post operative outcomes are measured are becoming ...
January 05, 2026 | Expert Insight | By editor@biopharmaapac.com
At the centre of this momentum stood the U.S. Food and Drug Administration, whose 2025 approvals illustrated how medicine is moving decisiv...
December 29, 2025 | Analysis | By arcilla.fran@biopharmaapac.com
The year 2025 has marked a pivotal moment for the biopharmaceutical industry as it reckons with the aftershocks of a global pandemic and ongoing geopolitic...
December 24, 2025 | Analysis
APAC Biopharma in Review: What Truly Moved the Needle This Year Asia-Pacific (APAC) has cemented its status as a pivotal biopharmaceutical hub in 2025, ma...
December 15, 2025 | Report
Biotechnology in 2025 is no longer confined to the laboratory bench. It is curing inherited blood disorders, changing how we prevent HIV, reimagining Alzhe...
December 10, 2025 | Report | By BioPharma APAC Wrap Up 2025
Health systems have become more consolidated. Some are acting as both providers and payers, and therefore have more influence as gatekeepers of market acce...
December 10, 2025 | Report
A protocol might specify a cohort defined by inflammatory markers, disease severity, a diagnostic pattern or a particular biological signature — but ...
December 10, 2025 | News | By Tom Stubbs, PHD – CEO of Hurdle.bio
Global pharmaceutical companies are racing to tap China’s new AI-powered biotech platforms to discover drugs faster and cheaper. In 2025, major Weste...
November 27, 2025 | Analysis
Acquisition adds a new growth vertical to Abbott's already high single-digit growth profile, gaining leadership in the fast-growing $60 billion U.S. canc...
November 21, 2025 | News
Vaxcellbio is betting on the combined power of nanobodies and advanced drug delivery science to push boundaries across ophthalmology and other chronic dise...
November 20, 2025 | Interaction
Most Read
Bio Jobs
News
Editor Picks